Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Immunotherapy

Posts tagged ‘IL-8’

View from Perdido Bay to Orange Beach

The sun is setting on the year end and the 2023 Holiday season brings our cancer conference coverage to a close until the new year.

Before we go, I wanted to end with a bang and highlight some really stunning and thoughtful research.

It was just published and is an absolutely amazing piece of thinking and execution.

Some of the best ideas come about in oncology R&D when we make the most of what’s already available biologically then borrow the concept so it can be applied therapeutically.

Rather than push the proverbial rock up the hill like Sisyphus, why not simply nudge it off the top and let nature take its course?

Sometimes even scientists are guilty of over-thinking things.

In this elegant work, the findings may well change the way we think about tackling some difficult to treat solid tumours going forward…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

The keynote address at the 2018 CRI CIMT EATI AACR International Cancer Immunotherapy Conference in New York last month was given by Ignacio Melero (Pamplona). Professor Melero gave an engaging and informative presentation entitled, “The immunotherapy faces of Interleukin–8 and CD137.” He also had a related talk on “4–1BB and Metabolism” at the Society for Immunotherapy of Cancer (SITC) meeting this weekend.

Pinning down new opportunities in IL-8 and 4-1BB

The late and sadly missed, Dr Holbrook Kohrt (Stanford), worked closely with Prof Melero on targeting CD137 or 4–1BB, as it’s more commonly known.

Regular readers may recall our interview wth Dr Kohrt back at Immunology 2015 in New Orleans (Link).

Professor Melero kindly spoke to BSB at SITC 2018 and shared his thoughts on where we are three years on and where his research is currently focused in relation to cytokines, and in particular, IL–8.

To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers

error: Content is protected !!